Pharmacokinetics and Safety of SHR0302 in Patients With Mild, Moderate Hepatic Impairment and Normal Liver Function in Phase I Clinical Study
Latest Information Update: 25 Mar 2025
At a glance
- Drugs Ivarmacitinib (Primary)
- Indications Alopecia areata; Atopic dermatitis; Crohn's disease; Rheumatoid arthritis; Systemic lupus erythematosus; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Jiangsu Hengrui Medicine Co.
Most Recent Events
- 13 Oct 2021 Status changed from recruiting to completed.
- 22 Jun 2020 Status changed from not yet recruiting to recruiting.
- 05 Mar 2020 New trial record